Engineers Gate Manager LP Sells 254,496 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Engineers Gate Manager LP cut its Elanco Animal Health stake by 75.2% in the second quarter, selling 254,496 shares and retaining 83,722 shares valued at approximately $2.06 million. Institutional investors collectively own 97.48% of the company.
• Analysts maintain a generally positive outlook, with one Strong Buy, nine Buy, two Hold and one Sell ratings; the consensus is “Moderate Buy” with an average price target of $29.09.
• Elanco beat quarterly expectations, reporting $0.34 in adjusted earnings per share versus a $0.27 estimate and $1.37 billion in revenue, up 10.2% year over year. Company insiders also purchased 63,198 shares worth approximately $1.47 million over the past 90 days.

Engineers Gate Manager LP reduced its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 75.2% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 83,722 shares of the company's stock after selling 254,496 shares during the period. Engineers Gate Manager LP's holdings in Elanco Animal Health were worth $2,060,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sapient Capital LLC boosted its holdings in Elanco Animal Health by 0.3% in the second quarter. Sapient Capital LLC now owns 128,573 shares of the company's stock valued at $3,164,000 after acquiring an additional 420 shares during the last quarter. Bessemer Group Inc. raised its holdings in Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company's stock worth $50,000 after purchasing an additional 525 shares during the last quarter. Fifth Third Wealth Advisors LLC raised its holdings in Elanco Animal Health by 4.2% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 14,273 shares of the company's stock worth $342,000 after purchasing an additional 579 shares during the last quarter. Root Financial Partners LLC lifted its position in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock valued at $40,000 after purchasing an additional 592 shares during the period. Finally, PNC Financial Services Group Inc. lifted its position in Elanco Animal Health by 4.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 23,875 shares of the company's stock valued at $540,000 after purchasing an additional 954 shares during the period. Institutional investors own 97.48% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. TD Cowen lifted their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, June 18th. Weiss Ratings upgraded shares of Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, September 4th. UBS Group raised their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Piper Sandler reaffirmed an "overweight" rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, Morgan Stanley upped their target price on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $29.09.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, CFO Robert Vanhimbergen purchased 4,200 shares of the company's stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $23.08 per share, with a total value of $96,936.00. Following the completion of the transaction, the chief financial officer directly owned 137,516 shares in the company, valued at $3,173,869.28. This trade represents a 3.15% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul Herendeen acquired 10,000 shares of the business's stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the acquisition, the director directly owned 111,687 shares in the company, valued at $2,644,748.16. This represents a 9.83% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 63,198 shares of company stock valued at $1,473,109 over the last 90 days. Insiders own 1.14% of the company's stock.

Elanco Animal Health Price Performance

Shares of ELAN stock opened at $23.02 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 12-month low of $18.22 and a 12-month high of $27.98. The firm has a fifty day moving average of $24.47 and a 200-day moving average of $23.87. The firm has a market capitalization of $11.50 billion, a price-to-earnings ratio of -56.16, a price-to-earnings-growth ratio of 1.72 and a beta of 1.68.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same period in the previous year, the company posted $0.26 earnings per share. The company's revenue for the quarter was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities research analysts forecast that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated NYSE: ELAN is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites, improve animal well-being and support productivity in livestock and aquaculture.

The company's products include vaccines, parasiticides, antibiotics, animal health pharmaceuticals and nutritional supplements. Its companion animal portfolio serves dogs and cats, while its livestock business provides products for cattle, poultry, swine and aquaculture operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.